A case of localized Castleman's disease with systemic involvement: Treatment and pathogenetic aspects

Annals of Hematology

Volumn 73, Issue 1, 1996, Pages 47-50

  Veldhuis, G J ^a   Van Der Leest, A H D ^a   De Wolf, J T M ^a   De Vries, E G E ^a   De Vellenga, E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anemia; Castleman's disease; Giant lymph node; Hyperplasia; Interleukin 6; Radiotherapy

Indexed keywords

INTERLEUKIN 6;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; ERYTHROPOIESIS; HUMAN; HUMAN CELL; IRON KINETICS; MALE; PRIORITY JOURNAL; SYMPTOM;

AGED; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE;

EID: 0030016289     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050201     Document Type: Article

References (36)

1. Aarden LA, de Groot ER, Schaap OL, Lansdorp PM (1987) Production of hybridoma growlh factor by human monocytes. Eur J Immunol 17:1411-1416
2. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM (1995) Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 86:1288-1291
3. Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602-605
4. Beguin Y, Stray SM, Cazzola M, Huebers HA, Finch CA (1988) Ferrokinetic measurement of erythropoiesis. Acta Haematol 79:121-126
5. Caslleman B, Iverson L, Pardo Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822-830
6. Cazzola M, Huebers HA, Sayers MH, Macphail P, Eng M, Finch CA (1985) Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood 66:935-939
7. 2. Proc Natl Acad Sci USA 85:8037-8041
8. de Wolf TM, Muller EW, Hendriks DH, Halie RM, Vellenga E (1994) Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood which is associated with ongoing differentiation. Blood 84:59
9. D'Hondt V, Humblet Y, Guillaume Th, Baatout S, Chatelain C, Berlière M, Longueville J, Feyens AM, De Greve J, Van Oosterom A, Von Graffenried B, Donnez J, Symann M (1995) Thrombopoietic effects and toxicity of IL-6 in patients with ovarian cancer before and after chemothrapy: a multicentric placebo controlled randomized phase Ib study. Blood 85:2347-2353
10. Diebold J, Tulliez M, Bernadou A, Audouin J, Tricot G, Reynes M, Bilski-Pasquier G (1980) Angiofollicular and plasmacytic polyadenopathy: a pseudotumorous syndrome with dysimmunity. J Clin Pathol 33:1068-1076
11. Flendrig JA, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119-120
12. Frizzera G (1985) Castleman's disease: more questions than answers. Hum Pathol 156:202-205
13. Frizzera G, Banks PM, Massarelli G, Rosai J (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Am J Surg Pathol 7:211-231
14. Frizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202-1216
15. Givon T, Slavin S, Haran-Ghera N, Michalevicz R, Revel M (1992) Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood 79:2392-2398
16. Hazenberg BPC, Limburg PC, Bijzet J (1988) SAA versus CRP serum levels in different inflammatory conditions, studied by ELISA using polyclonal anti-AA and monoclonal anti-SAA antibodies. In: Isobe T, et al (eds) Amyloid and amyloidosis. Plenum, New York, p 229
17. Helliwel PS, Marchesoni A, Peters M (1991) Cytadine deaminase activty, C reactive protein, histidine, and erythocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Ann Rheum Dis 50:362-365
18. Hsu S-M, Waldron JA, Xie S-S, Barlogie B (1993) Expression of interleukin-6 in Castleman's disease. Hum Pathol 24:833-839
19. Keller AR, Hochholzer L, Castleman B (1972) Hyaline vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670-683
20. Kobune M, Kohgo Y, Miyazaki E, Niitsu Y (1994) Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology 19:1468-1475
21. Le J, Vilcek J (1989) Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61:588-602
22. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D (1991) Interleukin-6 gene expression in Castleman's disease. Blood 78:2923-2930
23. Mulé JJ, McIntosh JK, Jablons DM, Rosenberg SA (1990) Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171:629-636
24. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EGE (1995) Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 86:900-905
25. Peterson B, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636-647
26. Schillings PHM, Flendrig JA (1969) Benign giant lymphoma: the morphological aspects. Folia Med Need 12:119-120
27. Stockenhuber F, Keil M, Wurnig C, Kurz RW, Gottsauner-Wolf M, Palcke P (1994) Impaired erythropoietin responsiveness in anemic rheumatoid arthritis patients: potential relation to immune mechanisms. Clin Sci 86:633-638
28. Stouthard JML, Goey H, de Vries EGE, de Mulder PH, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJM, Veenhof CHN (1996) Interleukin-6 as anti-tumour agent in renal cell carcinoma, (submitted for publication)
29. Tsukamuto Y, Hanada N, Nomura Y, Hiki Y, Kasai K, Shigematsu H, Kobayashi Y (1991) Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol 11:430-436
30. van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJM, Vellenga E, de Vries EGE (1994) Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84:1434-1441
31. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH (1995) Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 54:33-38
32. Veldhuis GJ, Willemse PHB, Sleijfer DT, van der Graaf WTA, Groen HJM, Limburg PC, Mulder NH, de Vries EGE (1995) Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non small cell lung cancer. J Clin Oncol 13:2585-2593
33. Vreugdenhil G, Lowenberg B, van Eijk HG, Swaak AJ (1990) Anemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 10:127-130
34. Weber J, Yang YC, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11:499-506
35. Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg SA (1994) A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother 15:292-302
36. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L. Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360-1367